Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial

IMPORTANCE: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. OBJECTIVE: To evaluate the safety and tolerability of an investigational CHIKV virus–like particle (VLP) vaccine in endemic regions. DESIGN, SETTING, AND P...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA
Päätekijät: Chen, Grace L., Coates, Emily E., Plummer, Sarah H., Carter, Cristina A., Berkowitz, Nina, Conan-Cibotti, Michelle, Cox, Josephine H., Beck, Allison, O’Callahan, Mark, Andrews, Charla, Gordon, Ingelise J., Larkin, Brenda, Lampley, Rebecca, Kaltovich, Florence, Gall, Jason, Carlton, Kevin, Mendy, Jason, Haney, Doug, May, Jeanine, Bray, Amy, Bailer, Robert T., Dowd, Kimberly A., Brockett, Brittanie, Gordon, David, Koup, Richard A., Schwartz, Richard, Mascola, John R., Graham, Barney S., Pierson, Theodore C., Donastorg, Yeycy, Rosario, Nicolas, Pape, Jean William, Hoen, Bruno, Cabié, André, Diaz, Clemente, Ledgerwood, Julie E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2020
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156994/
https://ncbi.nlm.nih.gov/pubmed/32286643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.2477
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia